Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021337 | 0.87 | GRM2 (0.43) | GRM2HCRTR1HCRTR2ALDH1A1GRIN2B | |
| SCHEMBL2019631 | 0.86 | GRM2 (0.42) | GRM2HCRTR1HCRTR2ALDH1A1TSHR | |
| SCHEMBL13613686 | 0.84 | ALDH1A1 (0.43) | GRM2ALDH1A1 | |
| SCHEMBL2024409 | 0.83 | GRM2 (0.41) | GRM2HCRTR1HCRTR2ALDH1A1GRIN2B | |
| SCHEMBL8270431 | 0.82 | GRM2 (0.51) | GRM2HCRTR1HCRTR2ALDH1A1TSHR | |
| SCHEMBL2029723 | 0.81 | GRM2 (0.56) | GRM2HCRTR1HCRTR2ALDH1A1TSHR | |
| SCHEMBL13613683 | 0.81 | PARP1 (0.52) | — | |
| SCHEMBL13613663 | 0.81 | GRM2 (0.56) | GRM2HCRTR1HCRTR2ALDH1A1TSHR | |
| SCHEMBL2024263 | 0.79 | GRM2 (0.54) | GRM2HCRTR1HCRTR2ALDH1A1TSHR | |
| SCHEMBL2026639 | 0.79 | GRM2 (0.47) | GRM2HCRTR1HCRTR2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885HCRTR1 260/4885HCRTR2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.